Department of Health and Human Services Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850



FY 2021 Inpatient Prospective Payment System (IPPS) New Technology Addon Payment (NTAP) Town Hall Meeting

Monday, December 16, 2019

<u>Public Comments on Substantial Clinical Improvement:</u> Comments for consideration in the IPPS proposed rule related to the substantial improvement criteria (including comments on the FY 2020 applications and on the town hall presentations) must be sent in writing to CMS via email to newtech@cms.hhs.gov or mailed to the address below. All comments must be received by 5:00 p.m. e.s.t. on Friday, January 3, 2020.

Comments may be sent to:

Centers for Medicare and Medicaid Services Att: New Technology; Mail stop C4-08-06 7500 Security Boulevard, Baltimore, MD 21244

Note: The Town Hall will take place in its entirety on one day on Monday, December 16, 2019. We are reserving Tuesday, December 17, 2019 as a snow day if we cannot hold the town hall meeting on Monday, December 16, 2019 due to inclement weather.

Times are Subject to Change Presentations are 15-minutes including Q&A

Time	Presenter
8:30-9:00a	Meeting Registration
9:00-9:05a	Opening Remarks: Carol Blackford, Director, Hospital and Ambulatory Policy Group, CMS
9:05-9:10a	Public comment:
9:10-9:15a	Public comment:
9:15-9:20a	Public comment:
9:20-9:35a	KTE-X19
9:40-9:55a	TECENTRIQ
10:00-10:15a	IDEFIRIX (Imlifidase)
10:20-10:35a	DownStream® System
10:40-10:55a	Terlivaz
11:00 -11:15a	Accelerate Pheno Test BC kit for use with Accelerate Pheno system
11:20-11:35a	ContaCT
11:40-11:55a	BioFire® FilmArray® Pneumonia Panel

Time	Presenter
12:00-12:15p	Soliris
12:15-12:55p	LUNCH BREAK
12:55-1:10p	BREYANZI (lisocabtagene maraleucel)
1:15-1:30p	EluviaTM Drug-Eluting Vascular Stent System
1:35-1:50p	The SpineJack® system
1:55-2:10p	Hemospray® Endoscopic Hemostat
2:15-2:30p	ZULRESSO
2:35-2:50p	The GammaTile TM
2:55-3:10p	IMFINZI (Durvalumab)
3:15-3:30p	WAVELINQ
3:35-3:50p	XENLETA TM (lefamulin)
3:55-4:10	CONTEPO

Wrap-Up and Conclusion